Logos Technologies Joins Medidata Solutions Technology Partner Program
ALPHADAS is a multi-study, schedule-driven, automated workflow system with staff and subject management tools, as well as barcoded sample tracking and management. It is designed to help sponsors and investigators around the world improve the speed, safety, quality and efficiency of Phase I trials, minimizing data queries while providing clean data in real time. A recent thorough QT study (TQT) study conducted at Spaulding Clinical Research in Westbend, Wis., showed that using ALPHADAS to collect and validate clinical data at the site produced virtually 100 percent accurate data. ALPHADAS also accepts patient data directly from clinical instrumentation, including vital sign systems, ECG devices and telemetry-based systems.
With this integration, sites can use ALPHADAS at the bedside, in the clinic and remotely, while sponsors benefit from a comprehensive view of a treatment’s trial data from all phases in one system, Medidata Rave. Moreover, with both the study metadata and study subject data captured in ALPHADAS rapidly moving to Rave, sponsors can take advantage of advanced Rave capabilities in data management, including easy query communication, coding and insightful reporting. The integration also enables sponsors using ALPHADAS for Phase I data capture to make use of Medidata Rave Safety Gateway, a configurable EDC-to-safety system interface that streamlines the reporting of serious adverse events by eliminating the need for duplicate data entry.
Logos Technologies joins the Medidata Technology Partner Program, which recognizes organizations with complementary technologies that support data sharing with Medidata products.
“Phase I research comes with unique challenges and workflow, and we’re always looking for ways to help sponsors improve that part of the process, whether it’s through our products or partnerships,” said Glen de Vries, president of Medidata Solutions. “Integrating with Logos allows ALPHADAS users to transition Phase I research into Medidata’s study management environment. Our joint customers will benefit from a rich set of data capture and management capabilities to handle their Phase I trials, as well as the ability to more easily view all study data in one system–Medidata Rave–for all phases of a study.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025